Blog
    Regulatory UpdateFor PhysiciansMay 7, 2026

    Peptide FDA Regulatory Status and FAERS Safety Analysis

    Review the March 2026 FDA regulatory status for BPC-157 and other peptides, alongside FAERS safety signals for Semaglutide including NAION and aspiration risks.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    1. Clinical Question

    What is the current regulatory landscape and safety profile for major clinical peptides as of March 2026, and what specific safety signals have emerged from post-marketing surveillance?

    2. Evidence Snapshot

    • Regulatory Status: 10 peptides analyzed for FDA approval and compounding eligibility (503A/503B).
    • Safety Signals: 10 distinct Adverse Event (AE) types identified for Semaglutide via FAERS.
    • Clinical Trials: Findings from the STEP 1, SELECT, SURMOUNT-1, and TESTS trials.
    • Common Safety Risk: Immunogenicity concerns cite as a primary factor in FDA Category 2 listings.

    3. What the Research Shows

    Regulatory and Compounding Status As of March 2026, a wide range of commonly used peptides are categorized by the FDA as having significant safety risks or lacking sufficient human clinical data. BPC-157, TB-500, GHK-Cu, CJC-1295, Ipamorelin, Selank, and Semax are not FDA-approved and are listed under Category 2. This designation indicates they are ineligible for routine compounding because of identified safety risks or a lack of clinical-need exemption.

    For BPC-157, the FDA specifically cites immunogenicity concerns and a lack of safety data. TB-500 likewise lacks human exposure data and presents immunogenicity risks. Several peptides have seen shifts in their status between September 2023 and September 2024. AOD-9604, CJC-1295, Selank, and Ipamorelin had their nominations withdrawn or were removed from consideration in late 2024.

    Thymosin Alpha-1 remains a substance of concern under interim policy despite being approved in over 35 countries as Zadaxin. It is not currently FDA-approved. Research into its clinical utility has yielded mixed results; in the phase III TESTS trial for sepsis, it failed to show a reduction in mortality.

    Safety Signal Analysis (GLP-1 RAs) Post-marketing surveillance of Semaglutide reveals a complex safety profile across several organ systems. Gastrointestinal events remain the most prevalent, with strong signals for nausea, vomiting, and delayed gastric emptying. The Ozempic label was updated in 2025 to include pulmonary aspiration risk, which may be contributed to by delayed gastric emptying during general anesthesia.

    Emerging signals of high clinical interest include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, prompting an EMA review in January 2025. Additionally, post-marketing data led to the addition of intestinal obstruction and ileus to the label. Psychologically, suicidal ideation remains under evaluation by the FDA, though current data do not support a risk higher than the general background population.

    Efficacy Benchmarks Clinical trials highlight varying degrees of efficacy across different indications. For obesity, Semaglutide (STEP 1) demonstrated 14.9% weight loss, while Tirzepatide (SURMOUNT-1) showed 22.5% loss. Retatrutide reported 24.2% weight loss at 12mg in Phase II. In cardiovascular outcomes, the SELECT trial showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tesamorelin achieved an 18% reduction in visceral adipose tissue (VAT) during pivotal Phase III trials for HIV lipodystrophy.

    4. Mechanism

    Based on available clinical data, the reported mechanisms and metabolic effects include:

    • Tesamorelin: Reduces visceral adipose tissue (VAT) in HIV lipodystrophy.
    • CJC-1295: Associated with increased heart rate.
    • Semaglutide: Induces delayed gastric emptying, which contributes to its primary effects and potential pulmonary aspiration risk during anesthesia.
    • Thymosin Alpha-1: Investigated as a vaccine adjuvant enhancer and for immunomodulation in sepsis.

    5. Limitations of the Evidence

    The primary limitation across the peptide landscape is the lack of human safety and exposure data. The FDA noted a near-total absence of human data for substances like TB-500. For compounded peptides, immunogenicity has been identified as a critical but under-studied risk. Many peptides, such as Selank and Semax, are approved in other jurisdictions (Russia) but lack the necessary evidence for FDA approval. Furthermore, signals like NAION for Semaglutide are based on emerging spontaneous reporting and require further formal review by regulatory bodies like the EMA.

    6. Clinical Takeaway

    Physicians should be aware that the regulatory environment for peptides shifted significantly between late 2023 and 2024, with many agents now listed under Category 2 for safety and immunogenicity concerns. For FDA-approved peptides like Semaglutide, clinical focus should remain on managing gastrointestinal side effects and monitoring for emerging signals such as NAION and pre-surgical pulmonary aspiration risks.

    7. Sources

    • FDA Regulatory Status Records (March 2026)
    • FAERS Safety Signals Database (Through Dec 2024/Jan 2025)
    • Clinical Trial Records: NCT03548935 (PMID: 33567185), NCT03574597 (PMID: 37952131), NCT04184622 (PMID: 35658024), NCT04881706 (PMID: 37351564), NCT00451282 (PMID: 18046028), NCT02867267 (PMID: 39814420).
    • FDA Warning Letters: Tailor Made Compounding (2020), Predator Nutrition (Oct 2020).

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1tb 500cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.